A detailed history of Huntington National Bank transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Huntington National Bank holds 215 shares of AXSM stock, worth $19,506. This represents 0.0% of its overall portfolio holdings.

Number of Shares
215
Previous 213 0.94%
Holding current value
$19,506
Previous $17,000 11.76%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$78.93 - $95.84 $157 - $191
2 Added 0.94%
215 $19,000
Q2 2024

Aug 08, 2024

SELL
$65.72 - $80.5 $8,083 - $9,901
-123 Reduced 36.61%
213 $17,000
Q1 2024

May 03, 2024

SELL
$69.39 - $97.64 $971 - $1,366
-14 Reduced 4.0%
336 $26,000
Q4 2023

Feb 07, 2024

BUY
$57.42 - $83.61 $114 - $167
2 Added 0.57%
350 $27,000
Q3 2023

Nov 08, 2023

SELL
$69.25 - $82.21 $900 - $1,068
-13 Reduced 3.6%
348 $24,000
Q2 2023

Aug 11, 2023

BUY
$58.41 - $90.35 $2,628 - $4,065
45 Added 14.24%
361 $25,000
Q1 2023

May 10, 2023

SELL
$58.39 - $75.0 $2,977 - $3,825
-51 Reduced 13.9%
316 $19,000
Q4 2022

Feb 09, 2023

BUY
$39.94 - $79.72 $1,437 - $2,869
36 Added 10.88%
367 $28,000
Q1 2022

May 10, 2022

SELL
$23.7 - $41.39 $23 - $41
-1 Reduced 0.3%
331 $14,000
Q4 2021

Jan 21, 2022

SELL
$30.7 - $43.36 $2,302 - $3,252
-75 Reduced 18.43%
332 $13,000
Q3 2021

Oct 28, 2021

BUY
$19.91 - $68.26 $1,393 - $4,778
70 Added 20.77%
407 $13,000
Q2 2021

Jul 30, 2021

BUY
$50.63 - $73.5 $3,189 - $4,630
63 Added 22.99%
337 $23,000
Q1 2021

Apr 12, 2021

BUY
$55.91 - $81.44 $15,319 - $22,314
274 New
274 $16,000
Q1 2020

Apr 27, 2020

SELL
$41.2 - $101.31 $20,600 - $50,655
-500 Closed
0 $0
Q4 2019

Jan 17, 2020

BUY
$16.71 - $106.24 $8,355 - $53,120
500 New
500 $52,000

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $3.89B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Huntington National Bank Portfolio

Follow Huntington National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Huntington National Bank with notifications on news.